Recent meta-analyses evaluating seven major AKI biomarkers across 31 studies found that CCL-14 demonstrated superior diagnostic efficacy with an overall AUC of 0.79, outperforming TIMP-2*IGFBP-7, sCysC (AUC 0.70), and NGAL (AUC 0.71). This evidence concerns the gene IGFBP7 and acute kidney injury.